dr. scagliotti on the phase iii ascend-5 study in alk nsclc
Published 7 years ago • 169 plays • Length 2:05Download video MP4
Download video MP3
Similar videos
-
6:37
ascend-4: upfront ceritinib in alk-rearranged nsclc
-
5:19
ascend-5: ceritinib for alk positive nsclc previously treated with crizotinib
-
1:37
dr. scagliotti discusses egfr mutations in nsclc
-
9:38
giorgio scagliotti:
-
6:04
case study: progression on alk inhibitors in nsclc
-
1:00
idr. giorgio scagliotti on taking a targeted approach to immunotherapy in lung cancer
-
5:52
ceritinib and alectinib in relapsed alk nsclc
-
1:52
dr. scagliotti on immunotherapy and precision medicine in lung cancer
-
0:56
dr. stinchcombe on the alta-1l trial in alk nsclc
-
6:27
alk inhibitor sequencing in nsclc
-
6:09
alk-positive nsclc: ascend-4 trial
-
1:48
dr. chow on the use of ceritinib in alk nsclc metastatic to the brain
-
4:10
crizotinib resistance in alk nsclc
-
1:07
dr. massarelli on first-line alk nsclc treatment
-
1:22
dr. crinò on crizotinib in alk nsclc
-
1:39
dr. leach on brigatinib in alk-positive nsclc
-
6:12
experience with ceritinib for alk nsclc
-
1:11
dr. salgia on crizotinib and other tkis in alk-positive nsclc
-
1:00
dr. hart on advances in alk nsclc